SG10201809518QA - Processes of preparing a jak1 inhibitor and new forms thereto - Google Patents

Processes of preparing a jak1 inhibitor and new forms thereto

Info

Publication number
SG10201809518QA
SG10201809518QA SG10201809518QA SG10201809518QA SG10201809518QA SG 10201809518Q A SG10201809518Q A SG 10201809518QA SG 10201809518Q A SG10201809518Q A SG 10201809518QA SG 10201809518Q A SG10201809518Q A SG 10201809518QA SG 10201809518Q A SG10201809518Q A SG 10201809518QA
Authority
SG
Singapore
Prior art keywords
preparing
processes
new forms
jak1 inhibitor
inhibitor
Prior art date
Application number
SG10201809518QA
Inventor
Jiacheng Zhou
Pingli Liu
Shili Chen
Yongzhong Wu
Dengjin Wang
Zhongjiang Jia
Lei Qiao
William Frietze
Michael Xia
Yingrui Dai
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG10201809518QA publication Critical patent/SG10201809518QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: 5 Ia as well as new forms of the inhibitor. N O F I G U R E 10
SG10201809518QA 2014-04-30 2015-04-29 Processes of preparing a jak1 inhibitor and new forms thereto SG10201809518QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986789P 2014-04-30 2014-04-30
US201461986738P 2014-04-30 2014-04-30

Publications (1)

Publication Number Publication Date
SG10201809518QA true SG10201809518QA (en) 2018-11-29

Family

ID=53264736

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201609016VA SG11201609016VA (en) 2014-04-30 2015-04-29 Processes of preparing a jak1 inhibitor and new forms thereto
SG10201809518QA SG10201809518QA (en) 2014-04-30 2015-04-29 Processes of preparing a jak1 inhibitor and new forms thereto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201609016VA SG11201609016VA (en) 2014-04-30 2015-04-29 Processes of preparing a jak1 inhibitor and new forms thereto

Country Status (20)

Country Link
US (2) US9802957B2 (en)
EP (1) EP3137471A1 (en)
JP (1) JP2017514832A (en)
KR (1) KR20170007331A (en)
CN (1) CN106687462A (en)
AU (1) AU2015253192B2 (en)
BR (1) BR112016025427A2 (en)
CA (1) CA2947418A1 (en)
CL (3) CL2016002748A1 (en)
CR (1) CR20160553A (en)
EA (1) EA201692193A1 (en)
EC (1) ECSP16088985A (en)
IL (1) IL248542B (en)
MA (1) MA39987A (en)
MX (1) MX2016014192A (en)
PE (1) PE20170300A1 (en)
PH (1) PH12016502177A1 (en)
SG (2) SG11201609016VA (en)
TW (1) TW201625643A (en)
WO (1) WO2015168246A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030235T2 (en) 2005-12-13 2017-04-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
EA020494B1 (en) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANENITRILE AS JAK INHIBITORS
MX347851B (en) 2010-03-10 2017-05-16 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors.
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AR086983A1 (en) 2011-06-20 2014-02-05 Incyte Corp DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
KR20220162825A (en) 2012-11-15 2022-12-08 인사이트 홀딩스 코포레이션 Sustained-release dosage forms of ruxolitinib
ES2649156T3 (en) 2013-01-14 2018-01-10 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
BR112015016793B1 (en) 2013-01-15 2021-12-28 Incyte Holdings Corporation COMPOUNDS OF THIAZOLACARBOXAMIDES AND PYRIDINECARBOXAMIDE, COMPOSITION COMPRISING THE SAME, METHOD OF INHIBITING THE ENZYME PIM1, PIM2, OR PIM3, AND USES OF SUCH COMPOUNDS
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
DK3786162T3 (en) 2013-05-17 2023-10-09 Incyte Holdings Corp BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
KR20160045081A (en) 2013-08-07 2016-04-26 인사이트 코포레이션 Sustained release dosage forms for a jak1 inhibitor
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US10064866B2 (en) 2014-04-08 2018-09-04 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
TW201625643A (en) * 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
NZ751284A (en) 2016-10-03 2022-09-30 Hangzhou Highlightll Pharmaceutical Co Ltd Novel jak1 selective inhibitors and uses thereof
EP3568396B1 (en) * 2017-01-11 2020-11-11 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
US11464744B2 (en) * 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
TW201924683A (en) 2017-12-08 2019-07-01 美商英塞特公司 Low dose combination therapy for treatment of myeloproliferative neoplasms
TWI797242B (en) 2018-01-30 2023-04-01 美商英塞特公司 Processes and intermediates for making a jak inhibitor
AU2019221667A1 (en) 2018-02-16 2020-10-01 Incyte Corporation JAK1 pathway inhibitors for the treatment of cytokine-related disorders
MA52655A (en) 2018-03-30 2021-02-17 Incyte Corp BIOMARKERS FOR INFLAMMATORY SKIN DISEASE
MX2022012285A (en) 2018-03-30 2023-08-15 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors.
WO2019200030A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
JP7431845B2 (en) 2018-10-31 2024-02-15 インサイト・コーポレイション Combination therapy for the treatment of blood disorders
CA3123596A1 (en) 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease
EP3934651A1 (en) 2019-03-05 2022-01-12 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2020191041A2 (en) 2019-03-19 2020-09-24 Incyte Corporation Biomarkers for vitiligo
CN117327083A (en) * 2019-06-06 2024-01-02 杭州高光制药有限公司 Synthesis method of furan imidazopyridines, crystal forms of furan imidazopyridines and crystal forms of salts thereof
WO2020244349A1 (en) * 2019-06-06 2020-12-10 广州高瓴制药有限公司 Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
JP2022551649A (en) 2019-10-10 2022-12-12 インサイト・コーポレイション Biomarkers for graft-versus-host disease
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP2023506118A (en) 2019-10-16 2023-02-15 インサイト・コーポレイション Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (LP)
BR112022024632A2 (en) 2020-06-02 2023-02-28 Incyte Corp PROCESSES FOR PREPARING A JAK1 INHIBITOR
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
MX2023002035A (en) 2020-08-18 2023-06-12 Incyte Corp Process and intermediates for preparing a jak1 inhibitor.
KR20230096973A (en) 2020-08-18 2023-06-30 인사이트 코포레이션 Methods and intermediates for preparing JAK inhibitors
MX2023006638A (en) 2020-12-04 2023-08-22 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases.
TW202237089A (en) 2020-12-08 2022-10-01 美商英塞特公司 Jak1 pathway inhibitors for the treatment of vitiligo
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor
WO2023250316A1 (en) * 2022-06-22 2023-12-28 Ptc Therapeutics, Inc. Compounds for treating spinocerebellar ataxia type 3
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
JP2513001B2 (en) * 1988-11-01 1996-07-03 山川薬品工業株式会社 Method for racemization of optically active tetrahydrofuran-2-carboxylic acid
JPH02225463A (en) * 1989-02-27 1990-09-07 Nissan Chem Ind Ltd Racemization of n-acetyl-indoline-2-carboxylic acid ester
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
FR2695126B1 (en) 1992-08-27 1994-11-10 Sanofi Elf Thienyl or pyrrolyl carboxylic acid derivatives, their preparation and medicaments containing them.
JP3178301B2 (en) * 1994-08-08 2001-06-18 東レ株式会社 Process for producing racemic aliphatic heterocyclic carboxylate
EP0727217A3 (en) 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical composition containing god-type ellagitannin as active ingredient
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP4516690B2 (en) 1998-08-11 2010-08-04 ノバルティス アーゲー Isoquinoline derivatives having angiogenesis inhibitory activity
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
PT1294358E (en) 2000-06-28 2004-12-31 Smithkline Beecham Plc MOORING PROCESS BY HUMIDITY
WO2002016370A1 (en) 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
EP1436291B1 (en) 2001-09-19 2009-01-14 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CN1582150B (en) 2001-10-30 2011-09-07 诺瓦提斯公司 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP1758892B1 (en) 2004-06-10 2012-10-17 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
US7683171B2 (en) 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
HUE030235T2 (en) 2005-12-13 2017-04-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
AU2007275577A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
WO2008079292A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
NZ585139A (en) 2007-11-16 2012-05-25 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors
ES2602577T3 (en) 2008-03-11 2017-02-21 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8344144B2 (en) 2008-06-18 2013-01-01 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
RU2560153C2 (en) 2008-06-20 2015-08-20 Дженентек, Инк. Jak-inhibiting triazolopyridine compounds and methods
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
AR076794A1 (en) 2009-05-22 2011-07-06 Incyte Corp DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZOL-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINS AS INHIBITORS OF THE JANUS KINASE AND COMPOSITIONS PHARMACEUTICS THAT CONTAIN THEM
EA020494B1 (en) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANENITRILE AS JAK INHIBITORS
WO2011003418A1 (en) 2009-07-08 2011-01-13 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
KR20140015162A (en) 2010-01-12 2014-02-06 에프. 호프만-라 로슈 아게 Tricyclic heterocyclic compounds, compositions and methods of use thereof
BR112012020693B1 (en) 2010-02-18 2020-05-12 Incyte Holdings Corporation CYCLLOBUTAN AND METHYLCYCLOBUTAN DERIVATIVES AS JANUS KINASE INHIBITORS AND COMPOSITION THAT UNDERSTANDS
MX347851B (en) 2010-03-10 2017-05-16 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors.
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR102024948B1 (en) 2011-02-18 2019-11-04 노파르티스 파르마 아게 mTOR/JAK INHIBITOR COMBINATION THERAPY
WO2012121361A1 (en) 2011-03-10 2012-09-13 第一三共株式会社 Dispiropyrrolidine derivative
AR086983A1 (en) 2011-06-20 2014-02-05 Incyte Corp DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
KR20220162825A (en) 2012-11-15 2022-12-08 인사이트 홀딩스 코포레이션 Sustained-release dosage forms of ruxolitinib
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
DK3786162T3 (en) 2013-05-17 2023-10-09 Incyte Holdings Corp BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
KR20160045081A (en) 2013-08-07 2016-04-26 인사이트 코포레이션 Sustained release dosage forms for a jak1 inhibitor
SG11201601119XA (en) * 2013-08-20 2016-03-30 Incyte Corp Survival benefit in patients with solid tumors with elevated c-reactive protein levels
ES2688553T3 (en) 2014-02-28 2018-11-05 Incyte Corporation JAK1 inhibitors for the treatment of myelodysplastic syndromes
US10064866B2 (en) 2014-04-08 2018-09-04 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
TW201625643A (en) 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1

Also Published As

Publication number Publication date
IL248542A0 (en) 2016-12-29
IL248542B (en) 2019-05-30
JP2017514832A (en) 2017-06-08
AU2015253192B2 (en) 2019-05-16
ECSP16088985A (en) 2017-02-24
US20150344497A1 (en) 2015-12-03
CN106687462A (en) 2017-05-17
US10450325B2 (en) 2019-10-22
PE20170300A1 (en) 2017-04-19
BR112016025427A2 (en) 2017-08-15
KR20170007331A (en) 2017-01-18
CA2947418A1 (en) 2015-11-05
CL2016002748A1 (en) 2017-05-19
US20180099978A1 (en) 2018-04-12
CR20160553A (en) 2017-04-25
MX2016014192A (en) 2017-05-01
MA39987A (en) 2017-03-08
WO2015168246A1 (en) 2015-11-05
EA201692193A1 (en) 2017-07-31
US9802957B2 (en) 2017-10-31
AU2015253192A1 (en) 2016-12-01
SG11201609016VA (en) 2016-11-29
TW201625643A (en) 2016-07-16
EP3137471A1 (en) 2017-03-08
CL2019002032A1 (en) 2019-11-29
PH12016502177A1 (en) 2017-02-06
CL2018001790A1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
PH12019501842A1 (en) Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MX2017006266A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12016501388A1 (en) Heteroaryls and uses thereof
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
MX2016015862A (en) Tank-binding kinase inhibitor compounds.
MX2020001278A (en) Synthesis of polycyclic-carbamoylpyridone compounds.
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
NZ730603A (en) Mk2 inhibitors and uses thereof
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2016010973A (en) Aminocarbonylcarbamate compounds.
MA39843A (en) Pyridine-2-amides useful as cb2 agonists
IL269695A (en) Compounds useful as inhibitors of alcat 1
PH12016501613A1 (en) Pyrazines modulators of gpr6
MX2018003903A (en) Bicyclic compound and use thereof for inhibiting suv39h2.
MX2019008375A (en) Thiobenzoimidazole as fungicides.
MX2019002017A (en) Sofosbuvir derivatives for the treatment of hepatitis c.
MX2016015298A (en) Nampt inhibitors and methods.
PH12017500492A1 (en) Crystalline bace inhibitors
IN2014MU00069A (en)
UA107885U (en) APPLICATION OF VINBORON FOR THE PREVENTION OF GUBROPHEN INDUCED BY GUSTROPATHY
TR201401763A2 (en) A composition for the treatment of sarcopenia
IN2013MU01524A (en)
IN2014MU00171A (en)